Axillary Management After Sentinel Lymph Node Biopsy in Breast Cancer Patients

Surgical Clinics of North America

Volumn 87, Issue 2, 2007, Pages 365-377

  Rivers, Aeisha ^a   Hansen, Nora ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; TAXANE DERIVATIVE;

ADJUVANT THERAPY; AXILLARY LYMPH NODE; AXILLARY LYMPH NODE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CLINICAL TRIAL; HORMONAL THERAPY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPHEDEMA; MASTECTOMY; METASTASIS; MICROMETASTASIS; MORBIDITY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; REVIEW; SENSORY DYSFUNCTION; SENTINEL LYMPH NODE BIOPSY; SURVIVAL; WOUND INFECTION;

AXILLA; BREAST NEOPLASMS; FEMALE; FORECASTING; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SURVIVAL RATE;

EID: 34247884373     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2007.01.014     Document Type: Review

References (49)

1. Fisher B., Wolmark N., Bauer M., et al. The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 152 (1981) 765-772
2. Dees E.C., Shulman L.N., Souba W.W., et al. Does information from axillary dissection change treatment in clinically node-negative patients with breast cancer?. Ann Surg 226 (1997) 279-287
3. Guiliano A.E., Dale P.S., Turner R.R., et al. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 222 (1995) 394-401
4. Engel J., Kerr J., Schlesinger-Raab A., et al. Axilla surgery severely affects quality of life: results of a 5-year prospective study in breast cancer patients. Breast Cancer Res Treat 79 (2003) 47-57
5. Kissen M.W., Querci della Rovere G., Easton D., et al. Risk of lymphoedema following the treatment of breast cancer. Br J Surg 73 (1986) 580-584
6. Ivens D., Hoe A.L., Podd T.J., et al. Assessment of morbidity from complete axillary dissection. Br J Cancer 66 (1992) 136-138
7. Erickson V.S., Pearson M.L., Ganz P.A., et al. Arm edema in breast cancer patients. J Natl Cancer Inst 93 (2001) 96-111
8. Cady B. The need to re-examine axillary lymph node dissection in invasive breast cancer. J Clin Oncol 15 (1997) 2345-2350
9. Krag D., Weaver D., Ashikaga T., et al. The sentinel node in breast cancer-a multicenter validation study. N Engl J Med 339 14 (1998) 941-946
10. Giuliano A.E., Kirgan D.M., Guenther J.M., et al. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 220 (1994) 391-398 [discussion: 398-401]
11. Giuliano A.E., Jones R.C., Brennan M., et al. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 15 (1997) 2345-2350
12. Borgstein P.J., Pijpers R., Comans E.F., et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 186 (1998) 275-283
13. Albertini J.J., Lyman G.H., Cox C., et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276 (1996) 1818-1822
14. Abdessalam S.F., Zervos E.E., Prasad M., et al. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg 182 (2001) 316-320
15. Jeruss J.S., Winchester D.J., Sener S.F., et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol 12 (2005) 34-40
16. Rouzier R., Extra J.M., Klijanienko J., et al. Incidence and prognostic significance of complete axillary downstaging in breast cancer patients with T1 to T3 tumors and cytologically proven axillary metastatic lymph nodes. J Clin Oncol 20 (2002) 5-10
17. Kuerer H.M., Sahin A.A., Hunt K.K., et al. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 230 (1999) 72-78
18. Calhoun K.E., Hansen N.M., Turner R.R., et al. Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary dissection. Am J Surg 190 (2005) 588-591
19. Menes T.S., Tartter P.I., Mizrachi H., et al. Breast cancer patients with pN0(i+) and pN1(mi) sentinel nodes have high rate of nonsentinel node metastases. J Am Coll Surg 200 3 (2005) 323-327
20. Fisher B., Jeong J.H., Anderson S., et al. Twenty-five year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347 (2002) 567-575
21. Fisher B., Montague E., Redmind C., et al. Findings from NSABP Protocol No. B-04. Comparison of radical mastectomy with alternative treatments for primary breast cancer. Cancer 46 (1980) 1-13
22. Wright F.C., Walker J., Law L., et al. Outcomes after localized axillary node recurrence in breast cancer. Ann Surg Oncol 10 (2003) 1054-1058
23. Clemons M., Danson S., Hamilton T., et al. Locoregionally recurrent breast cancer: incidence, risk factors, and survival. Cancer Treat Rev 27 (2001) 67-82
24. Morton D.L., Wen D.R., Wong J.H., et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127 4 (1992) 392-399
25. Krag D.N., Weaver D.L., Alex J.C., et al. Surgical resection and radiolocalization of the sentinel node in breast cancer using gamma probe. Surg Oncol 2 (1993) 335-340
26. Veronesi U., Paganelli G., Galimberti V., et al. Sentinel node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph nodes. Lancet 349 (1997) 1864-1867
27. McMasters K.M., Wong S.L., Tuttle T.M., et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes. Ann Surg 231 5 (2000) 724-731
28. Miltenberg D.M., Miller C., Karamlou T.B., et al. Meta-analysis of sentinel lymph node biopsy in breast cancer. J Surg Res 84 2 (1999) 138-142
29. Smidt M.L., Janssen C.M., Kuster D.M., et al. Axillary recurrence after a negative sentinel node biopsy for breast cancer: incidence and clinical significance. Ann Surg Oncol 12 1 (2004) 29-33
30. Naik A.M., Fey J., Gemignani M., et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection. Ann Surg 240 3 (2004) 462-471
31. Badgwell B.D., Povoski S.P., Abdessalam S.F., et al. Patterns of recurrence after sentinel lymph node biopsy for breast cancer. Ann Surg Oncol 10 4 (2003) 376-380
32. Giuliano A.E., Haigh P.I., Brennan M.B., et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 18 (2000) 2553-2559
33. Newman LA. The practice of lymphatic mapping and sentinel lymph node biopsy for breast cancer patients. J Oncology Practice; in press.
34. Guenther J.M., Hansen N.M., Difronzo L.A., et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg 138 (2003) 52-56
35. Marschall J., Nechala P., Colquhoun P., et al. Reassessing the role of axillary lymph node dissection in patients with early stage breast cancer. Can J Surg 46 (2003) 285-289
36. Hughes K.S., Schnaper L., Berry D., et al. Lumpectomy plus tamoxifen with and without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 351 10 (2004) 971-977
37. American College of Surgeons Oncology Group, home page. Available at: www.acosog.org/. Accessed September 1, 2006.
38. White R.L., and Wilke L.G. Update on the NSABP and ACOSOG breast cancer sentinel node trials. Am Surg 70 (2004) 420-424
39. Posther K.E., Wilke L.G., and Guiliano A.E. Sentinel lymph node dissection and the current status of American trials on breast lymphatic mapping. Semin Oncol 31 3 (2004) 426-436
40. Wilke L.G., Mccall L.M., Posther K.E., et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 13 4 (2006) 491-500
41. Leitch A.M., McCall L., Beitsch P., et al. Factors influencing accrual to ACOSOG Z0011, a randomized phase III trial of axillary dissection vs. observation for sentinel node-positive breast cancer. J Clin Oncol 24 18S (2006) 601 [2006 ASCO Annual Meeting Proceedings Part I]
42. Wilke L.G., and Giuliano A. Sentinel lymph node biopsy in patients with early stage breast cancer: status of the National Clinical Trials. Surg Clin North Am 83 (2003) 901-910
43. Van Zee K.J., Manasseh D.M., Bevilacqua J.L., et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 10 (2003) 1140-1151
44. Degnim A.C., Griffith K.A., Sabel M.S., et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer 98 (2003) 2307-2315
45. Mansel R.E., Fallowfeld L., Kissin M., et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial. J Natl Cancer Inst 98 9 (2006) 599-609
46. Julian T.B., Krag D., Brown A., et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. Breast Cancer Res Treat 88 (2004) S11
47. Chu K.U., Turner R.R., Hansen N.M., et al. Sentinel node metastasis in patients with breast carcinoma accurately predicts immunohistochemically detectable nonsentinel node metastasis. Ann Surg Oncol 6 (1999) 756-761 24
48. Viale G., Maiorano E., Pruneri G., et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg 241 2 (2005) 319-325
49. Katz A., Niemierko A., Gage I., et al. Can axillary dissection be avoided in patients with sentinel lymph node metastasis?. J Surg Oncol 93 (2006) 550-558